Medivir proceeds with a separation of the company’s operations
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has tasked the company management to continue the implementation of a separation of the company’s operations into two independent companies, with the intention to obtain a separate listing on First North Premium for the new commercial company based on Medivir’s current pharmaceutical portfolio. The objective of the separation is to visualize the value of both the commercial operations and the pharmaceutical projects that make up the R&D portfolio. The Board´s target timing is that a